مقالات رزومه علیرضا سوری

 The World Health Organization has identified leishmaniosis as one of the eight major tropical parasitic diseases in the world. Every year, from 0.7 million to 1.3 million new cases of cutaneous leishmaniasis (CL) are registered in the world. Cutaneous leishmaniasis is still a great health problem in Iran. Of the total annual cases of leishmaniasis in Iran, about 80% are related to rural cutaneous leishmaniasis, 5% to visceral leishmaniasis and the rest are related to urban cutaneous leishmaniasis. this study aimed to investigate the epidemiological factors in patients with cutaneous leishmaniasis.

 A total of 2119 patients afflicted with cutaneous leishmaniosis due to skin lesions were examined. The data were analyzed after entering the data into SPSS software, vol 26. Tables and graphs were used for displaying the qualitative variables; central indicators and dispersion were used for indicating quantitative variables, and chi-square test was used for analyzing the data. The level of P ≤ 0.05 was considered as the level of significance.

 The mean age of 2119 patients was 28.32 ± 20.38 years. Furthermore, 65.2% of male patients and 34.8% of female ones were infected with the disease. As for the nationality of the patients, 81.8% of them were Iranians and 18.1% of them were Afghans, and 88.9% of them had a history of traveling to other areas. More than 51% of the cases occurred in the young age group, the age group of 21 to 30 years had the highest incidence (18.4%), and the incidence trend of the disease did not decrease. There was a statistically significant relationship between patients’ nationality and travel history, gender, and occupation (P = 0.0001). There was no statistically significant relationship between the incidence season and travel history (P = 0.221).

 Due to the patients’ travel to endemic areas, providing them with training on effective methods for preventing mosquito bites may have had a great impact on reducing the incidences of cutaneous leishmaniosis in travelers.

Despite inconsistencies in existing studies, the results of some research studies indicate that treatment with estrogen priming and gonadotropin-releasing hormone (GnRH) antagonist look promising for poor-responder patients.

The study was conducted on 2 groups of poor-responder patients under treatment with GnRH antagonist and gonadotropin. Each group had 53 patients. The treatment was performed after considering the patients’ age, the number of previously failed in-vitro fertilization (IVF), antral follicles count and mean serum level of follicular stimulating hormone (FSH3), anti-Müllerian hormone (AMH), and estradiol (E2). In the intervention group, 4 mg of estradiol valerate was administered daily from the 21st day of the cycle before IVF and continued up to the second day of the cycle. Then, stimulation was initiated with human menopausal gonadotropin (HMG) and follicle-stimulating hormone (FSH) and the GnRH antagonist was implemented on the eighth day and continued until the prescription of human chorionic gonadotropin (HCG).

The average number of obtained large follicles (2.9±1.8 against 2.3±1.6), M2 oocytes (3.6±0.3 against 2.8±0.3) and embryo quality type II (1.3±0.2 against 0.9±0.1) and type III (0.7±0.1 against 0.3±0.1) in the intervention group was significantly higher compared to the control group (P value was respectively 0.05, 0.05, 0.05, and 0.01). The rate of successful pregnancy was higher in the intervention group (8.3%) than in the control group (6.7%). However, it was not statistically significant (P = 0.50).

Estrogen priming has positive effects on GnRH antagonist cycles with an increase in the number of large follicles and better quality oocytes and embryos.